Who we are
The Incisive team is well-resourced and experienced in:
Clinical trial design
Regulatory pathways especially devices
Business development & management
The team enjoys strong global networks with dentists & orthodontists, who contribute to product development.
The principals of Incisive are shown below as well as key advisors, critical to our success.
Allan Myers AC, QC
ALLAN MYERS AC, QC – Founding investor, barrister, commercial lawyer, businessman. Allan is a pre-eminent barrister with many areas of expertise, including commercial law and international arbitration. He holds many positions of responsibility, including Chancellor of The University of Melbourne and Governor of the Ian Potter Foundation. Allan is a director of publicly listed companies in Europe and many private and unlisted companies in Australia and elsewhere.
Jonathan Mangum, PhD
Jon invented the BlueCheck technology and is a driving force in its commercial development through his service with Incisive Technologies as a company founder and director. An award-winning scientist with over 15 years of experience in biomedical research, Jon leads the team at the University of Melbourne that supports the development of BlueCheck.
Kerry Hegarty, PhD
Kerry has worked over the last 30 years creating global businesses based on early-stage technologies, translating benchtop science to global sales. She served as Managing Director/CEO of Sienna Cancer Diagnostics where she built the technical and business development teams whilst creating strategic partnerships, which ultimately led to delivering a novel diagnostic test for bladder cancer to the US market and elsewhere.
Chief financial officer
Campbell Robertson-Smith, CA
Campbell is a Chartered Accountant with over seven years’ experience working in both advisory firms and business management teams. Campbell is a key member of Dunkeld Pastoral Company’s finance team, the principal investor of Incisive. Campbell manages the day-to-day finances of Incisive, as well as offering strategic advice on R&D tax planning, capital access and partnering.
Centre for Biopharmaceutical Excellence
CBE is a group of highly experienced professionals who have proven track records with hands-on expertise in managing and directing operations within the life sciences industry – in companies large and small. We come together to provide complementary consulting services to this complex industry, specialising in biopharmaceutical products. Our team of professionals offers a broad, deep and diverse experience in the key areas of Quality, Engineering, Manufacturing Operations, Supply Chain, R&D and Scientific/Technical Due Diligence. CBE has capability across many sectors including biologics, blood products, vaccines, APIs, drugs, sterile products, diagnostics and medical devices.
Specifically, Steve Williams (Director-CBE) has assisted Incisive with establishing its QMS and manufacturing program. Steve has over 40 years experience in the biotechnology, pharmaceutical and medical device industries in Quality Systems, Compliance and Manufacturing, including 25+ years consulting in GxP Quality Management and Regulatory Compliance.
Jeff Davies (Director-CBE) has more than 30 years experience in the biopharmaceutical industry. He has eight years of general management experience with CSL with oversight on the manufacture and supply of plasma products, influenza vaccines, anti-venoms and diagnostic products, and the in-licensing of pharmaceuticals and vaccines. Steve, Jeff and the CBE team have helped Incisive in defining and implementing key strategies during the early stages of manufacturing and partnering. More about Steve and Jeff can be found here.
global market experts
Biointelect is a strategic planning and commercialisation consultancy, bringing science to the marketplace. We provide a range of services for biopharmaceutical, medical device and IVD companies seeking to commercialise new technologies globally.
Our clients are either entering new markets or new therapeutic areas, and need to adapt their organisation and business processes to optimise their effectiveness, or have limited resources to be able to focus and effectively execute key projects. Biointelect helps clients to develop and drive strategy, identify and evaluate new business opportunities and find the right partners. For early stage companies we provide commercial and market insights to support product development. We can also assist with portfolio prioritisation and partnering. For late stage companies, we have a proven track record in new product planning, start-up development and identifying the right commercial partners.
Each member of the Biointelect management team has greater than 20 years’ experience and proven track records in small start-up ventures and multinational corporations. We, therefore, understand our client’s needs. We have successfully managed business units or companies and navigated complex regulatory, clinical research, quality management, commercial, product launches and business partnering strategies. Our consulting philosophy is to always offer a personalised and adaptable service. We take ownership of our projects seriously and strive for success as if we were part of your team.
GUILLAUME HERRY, MBA – Guillaume has worked in the United States, Europe and Australia in the biopharmaceutical and medical device industries, spanning across new product development, strategic planning, business development & licensing and general management. As part of Biointelect, Guillaume advises companies seeking to commercialise new technologies globally.
Griffith Hack helps build, protect and grow businesses through Intellectual Property (IP). Our multidisciplinary team delivers the highest quality technical, legal and financial perspectives on IP, from research and development through to market.
Our people actively listen to understand our clients’ innovations, challenges and business objectives. We pride ourselves on the quality of our work, industry understanding and responsiveness.
Dr Malcolm Lyons prepared the patent application covering Incisive Technologies’ lead compound, then assisted obtaining patents covering the lead compound in key jurisdictions, and is now guiding the US patent process, where patenting diagnostic tools can be challenging. Please see here for Malcolm’s profile.